Person-centered choice and mHealth support for same-day delivery of long-acting injectable cabotegravir (ImPrEP CAB Brasil): a prospective, open-label, multicenter, quasi-experimental implementation study Authors: Thiago Silva Torres, Brenda Hoagland, Carolina Coutinho, Mayara Secco Torres Silva, Ronaldo Ismério Moreira, Iuri Costa Leite, Marcelo Cunha, Emilia M. Jalil, Sandra Wagner Cardoso, Roberta Trefiglio, Alessandro Farias, Maria Paula G. Mourão, José Valdez Madruga, Josué N. de Lima, Ronaldo Zonta, Gabrielle O'Malley, Julio Moreira, Keila Simpson, Heather A. Pines, Alex R. Rinehart, Nanlesta Pilgrim, Paula M. Luz, Marcos Benedetti, Maria Cristina Pimenta, Valdilea Gonçalves Veloso, Beatriz Grinsztejn, ImPrEP CAB Brasil Study Group Published: 2026 ABSTRACT SummaryBackgroundLong-acting injectable cabotegravir (CAB-LA) offers a promising alternative to daily oral PrEP. However, studies evaluating PrEP choice and mHealth tools designed to support informed PrEP decision-making in real-world public health settings are scarce. We evaluated PrEP choice and the impact of an mHealth tool.MethodsImPrEP CAB Brasil is a prospective, multicenter, quasi-experimental, implementation study conducted in six public health services in Brazil. Eligible participants were PrEP-naïve cisgender men, transgender and non-binary persons who have sex with men, aged 18–30 years, who tested negative for HIV. Participants were offered a person-centered model that provided a choice between same-day delivery of CAB-LA and oral PrEP. To support informed decision-making, participants were allocated (1:1) to standard-of-care counseling (SOC) or mHealth tool + SOC (first half enrolled in each site received SOC and the remaining received mHealth + SOC). Modified Poisson regression models estimated the effects of exposures of interest, study arm and Decisional Conflict Scale (DCS), on CAB-LA choice. Registered at ClinicalTrials.gov (NCT05515770).FindingsFrom October-2023 to October-2024, 1447 participants were enrolled: 738 (51.0%) to SOC arm and 709 (49.0%) to mHealth + SOC arm. Overall, 1201 (82.9%) participants chose CAB-LA. Participants allocated to mHealth + SOC arm were more likely to choose CAB-LA compared to SOC (PR: 1.15; 95% CI 1.10–1.21). Higher DCS scores were associated with a lower prevalence ratio of choosing CAB-LA (PR: 0.99; 95% CI 0.98–0.99). A total of 678 (95.7%) participants were satisfied with the mHealth tool and 659 (92.9%) found it supported PrEP decision.InterpretationWe found a strong preference for CAB-LA among young sexual and gender diverse populations. The mHealth intervention was highly acceptable and supported informed-decision, indicating its utility as a scalable strategy in real-world settings. These findings are crucial for guiding the equitable scale-up of CAB-LA and advancing HIV prevention in Latin America.FundingUnitaid, WHO, Brazilian Ministry of Health. Research in contextEvidence before this studyAlthough the global HIV landscape is promising, significant challenges persist. In Latin America, new HIV cases continue to increase and late diagnoses are common. Daily oral tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg (TDF/FTC) pre-exposure prophylaxis (PrEP) is highly effective in reducing HIV incidence. However, oral PrEP implementation faces significant real-world challenges related to adherence, access, stigma associated with daily pill-taking, and competing life events that often lead to discontinuation. The introduction of the highly efficacious long-acting injectable cabotegravir 600 mg (CAB-LA) PrEP represents a significant advancement in HIV prevention. Expanding the range of PrEP options, including both daily oral and long-acting injectable methods, empowers individuals to select the modality that best fits their needs and circumstances, reinforcing the importance of person-centered choices in HIV prevention strategies.We conducted a PubMed search on March 6, 2026, with no restrictions on publication date or language, using the keywords “PrEP” or “pre-exposure prophylaxis”, combined with “cabotegravir” and “choice” or “person-centered”. We identified one large study reporting results of PrEP choice with cabotegravir. The study was an extension of three randomized trials conducted in rural Uganda and Kenya. The intervention provided person-centered choice of oral PrEP, HIV post-exposure prophylaxis (PEP) or CAB-LA, with the option to switch according to participant preference. Overall, 274 (56%) of 485 participants who received the intervention chose CAB-LA. We found other studies presented in international conferences, such as HPTN 083 and HPTN 084 clinical trials open-label extension. However, no studies among sexual and gender diverse populations on PrEP choice within an implementation study were found.Added value of this studyThe ImPrEP CAB Brasil study makes a significant contribution to the literature as the most extensive implementation study of CAB-LA PrEP conducted in Latin America. Our study provides critical real-world evidence for policymakers and program implementers within the Brazilian Public Health System (Sistema Único de Saúde, SUS). We offered young sexual and gender minorities aged 18–30 years a person-centered choice between CAB-LA and oral PrEP. The study also evaluated the acceptability of an mHealth intervention tool to support PrEP choice, addressing a significant gap in the literature on mHealth tools for this purpose. The mHealth tool was highly acceptable to participants (over 90% found it easy to use, comprehensible, useful, and satisfying) and significantly increased the prevalence ratio of choosing CAB-LA. Furthermore, the study detailed the primary reasons for selecting each PrEP modality, which were “difficulty remembering to take a daily pill” for CAB-LA to “not liking injections” for oral PrEP, offering actionable insights for tailored counseling and implementation strategies.Implications of all the available evidenceOur findings highlight the urgent need for person-centered approaches for PrEP choice. The strong preference for CAB-LA, alongside the proven effectiveness of both CAB-LA and oral PrEP, demonstrates that enabling individual choice is essential for increasing PrEP uptake and expanding coverage. Additionally, the high acceptability and utility of the mHealth tool suggests it is a promising, scalable strategy for delivering comprehensive education and supporting informed decision-making. This is crucial to overcoming barriers and advancing equitable access, particularly among populations with increased vulnerability to HIV. A comprehensive PrEP service should integrate the best PrEP options available, enhanced by accessible, choice promoting interventions, to significantly reduce new HIV acquisitions and improve public health outcomes. Research in context Evidence before this study Although the global HIV landscape is promising, significant challenges persist. In Latin America, new HIV cases continue to increase and late diagnoses are common. Daily oral tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg (TDF/FTC) pre-exposure prophylaxis (PrEP) is highly effective in reducing HIV incidence. However, oral PrEP implementation faces significant real-world challenges related to adherence, access, stigma associated with daily pill-taking, and competing life events that often lead to discontinuation. The introduction of the highly efficacious long-acting injectable cabotegravir 600 mg (CAB-LA) PrEP represents a significant advancement in HIV prevention. Expanding the range of PrEP options, including both daily oral and long-acting injectable methods, empowers individuals to select the modality that best fits their needs and circumstances, reinforcing the importance of person-centered choices in HIV prevention strategies. We conducted a PubMed search on March 6, 2026, with no restrictions on publication date or language, using the keywords “PrEP” or “pre-exposure prophylaxis”, combined with “cabotegravir” and “choice” or “person-centered”. We identified one large study reporting results of PrEP choice with cabotegravir. The study was an extension of three randomized trials conducted in rural Uganda and Kenya. The intervention provided person-centered choice of oral PrEP, HIV post-exposure prophylaxis (PEP) or CAB-LA, with the option to switch according to participant preference. Overall, 274 (56%) of 485 participants who received the intervention chose CAB-LA. We found other studies presented in international conferences, such as HPTN 083 and HPTN 084 clinical trials open-label extension. However, no studies among sexual and gender diverse populations on PrEP choice within an implementation study were found. Added value of this study The ImPrEP CAB Brasil study makes a significant contribution to the literature as the most extensive implementation study of CAB-LA PrEP conducted in Latin America. Our study provides critical real-world evidence for policymakers and program implementers within the Brazilian Public Health System (Sistema Único de Saúde, SUS). We offered young sexual and gender minorities aged 18–30 years a person-centered choice between CAB-LA and oral PrEP. The study also evaluated the acceptability of an mHealth intervention tool to support PrEP choice, addressing a significant gap in the literature on mHealth tools for this purpose. The mHealth tool was highly acceptable to participants (over 90% found it easy to use, comprehensible, useful, and satisfying) and significantly increased the prevalence ratio of choosing CAB-LA. Furthermore, the study detailed the primary reasons for selecting each PrEP modality, which were “difficulty remembering to take a daily pill” for CAB-LA to “not liking injections” for oral PrEP, offering actionable insights for tailored counseling and implementation strategies. Implications of all the available evidence Our findings highlight the urgent need for person-centered approaches for PrEP choice. The strong preference for CAB-LA, alongside the proven effectiveness of both CAB-LA and oral PrEP, demonstrates that enabling individual choice is essential for increasing PrEP uptake and expanding coverage. Additionally, the high acceptability and utility of the mHealth tool suggests it is a promising, scalable strategy for delivering comprehensive education and supporting informed decision-making. This is crucial to overcoming barriers and advancing equitable access, particularly among populations with increased vulnerability to HIV. A comprehensive PrEP service should integrate the best PrEP options available, enhanced by accessible, choice promoting interventions, to significantly reduce new HIV acquisitions and improve public health outcomes. Introduction In 2024, global HIV acquisitions reached their lowest level since the late 1980s, marking a 40% decline since 2010.1 However, with 1.3 million new acquisitions in 2024, the incidence remains alarmingly high, surpassing the United Nations target for 2025 by more than threefold.1 Despite global reductions until 2024, Latin America has experienced a 13% increase in new HIV cases during the same period.1 Progress in the region has slowed down, with the 95–95–95 targets not being met and late diagnoses persisting among people living with HIV.1 Outcomes are worse among key populations who continue to face limited access to HIV services due to structural barriers and persistent stigma, discrimination, violence, and other human rights violations.2 Daily oral tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg (TDF/FTC) pre-exposure prophylaxis (PrEP) is highly effective in reducing HIV incidence when made widely available.3 However, oral PrEP implementation faces significant real-world challenges, including poor adherence, difficulties in access, low self-perceived risk, reluctance to take daily pills, stigma, and competing life events.4 HIV continues to impact sexual, gender, racial, and ethnic minority populations, who often fail to realize the full benefits of PrEP. This disparity is driven by systemic barriers to PrEP access and uptake, along with challenges in sustaining long-term adherence to daily oral regimens. Brazil has offered PrEP free of charge at the point of care through the country's Public Health System (Sistema Unico de Saúde, SUS) since 2017. Nevertheless, significant disparities in access to PrEP persist. By April 2026, 80% of 153,529 persons using oral PrEP were gay and other cisgender men who have sex with men (MSM), predominantly white, aged 30 years or older, and with high levels of education. This profile contrasts sharply with those most frequently acquiring HIV, as the incidence in the country is rising among young Black persons.5,6 This mismatch underscores that many people who could benefit from PrEP are still being left behind, highlighting critical gaps in equitable access and outreach efforts. This epidemiological gap provides the rationale for evaluating alternative prevention modalities and decision-making support tools in Brazil. Long-acting injectable cabotegravir 600 mg (CAB-LA) PrEP was shown to be superior to daily oral TDF/FTC PrEP for HIV prevention.7,8 Although the high efficacy of CAB-LA PrEP is reassuring, ongoing implementation studies are essential to evaluate its real-world acceptability, feasibility, and integration into scalable HIV prevention programs. The availability of multiple PrEP modalities is particularly important, as choice empowers individuals to select the option that best meets their preferences and circumstances. For instance, the SEARCH Dynamic Choice study in rural Kenya and Uganda demonstrated that providing a patient-centered choice between oral PrEP, CAB-LA and HIV post-exposure prophylaxis (PEP) with the flexibility to switch between modalities significantly increased prevention coverage compared to standard of care.9 Decision-making support tools for HIV prevention modalities grounded in the Ottawa Decision Support Framework10 and International Patient Decision Aid Standards Collaboration11 are being developed globally. Although mHealth tools have shown to be feasible and acceptable in promoting the PrEP care continuum,12 few studies have evaluated the use of these tools in the context of PrEP choice. The MyPrEP tool, a website that allows users to review modules with information about HIV prevention methods, including PrEP effectiveness, dosing, side effects and safety, has shown to increase PrEP uptake among women aged 18–25 years in South Africa.13 Despite high willingness to use long-acting PrEP in Latin America,14,15 there is a critical gap in evidence-based, culturally-tailored mHealth tools designed to support informed PrEP choice within public health systems, such as the Brazilian SUS. The ImPrEP CAB Brasil study, the largest CAB-LA PrEP implementation study in Latin America, aims to generate critical evidence to inform national policies and program implementers about how injectable CAB-LA PrEP can be provided in the context of SUS. Here we describe two implementation outcomes: (1) choice between CAB-LA and oral PrEP (adoption); (2) acceptability of the mHealth intervention tool developed to support informed decision-making and adoption of CAB-LA. We used modified Poisson regression models to estimate the effects of the mHealth tool and the Decisional Conflict Scale (DCS) on CAB-LA choice. Methods Study design ImPrEP CAB Brasil is a prospective, open-label, multicenter, quasi-experimental implementation study conducted in six services providing PrEP as part of SUS in Campinas, Florianópolis, Manaus, Rio de Janeiro, Salvador and São Paulo. Sites were selected to ensure geographic representation across Brazil's North, Northeast, South, and Southeast regions, focusing on urban centers with high HIV prevalence and established PrEP services. Eligible participants were cisgender men, transgender women, transgender men and non-binary persons who have sex with men, aged 18–30 years, that tested HIV negative and were PrEP naive. Exclusion criteria included identifying as a cisgender woman, PEP indication and silicone implants in buttocks. Details of the ImPrEP CAB Brasil study and its protocol have been described elsewhere.16 Here we describe a cross-sectional analysis using data collected at enrollment. The institutional review board (IRB) at Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (Rio de Janeiro, Brazil; #CAAE 59166522.7.1001.5262) approved the study. Ethical approvals were also obtained from the World Health Organization (WHO) Research Ethics Review Committee (ERC) and local IRBs at each site. All study participants provided written informed consent in Portuguese before enrollment. The study has been registered at clinicaltrials.gov (NCT05515770). This study followed the standards for Reporting Implementation Studies (StaRI) Statement. Procedures Individuals approaching the sites seeking PrEP or HIV testing were asked if they were interested in assessing an educational and counseling intervention for PrEP choice. Participants were screened using a third-generation rapid test (TR DPP® HIV-1/2 Bio-Manguinhos, Rio de Janeiro, Brazil; Abon HIV 1/2/O TRI-LINE—Abbott, Hangzhou, China; Bioclin HIV Tri Line—Quibasa, Belo Horizonte, Brazil; or HIV 1 + O/2 Assure Tech, Hangzhou, China) according to the Brazilian HIV testing algorithm. Individuals with confirmed HIV positive tests were immediately linked to care and offered antiretroviral therapy (ART) through SUS. Participants with HIV negative tests without immediate indication for PEP were considered eligible and, after providing written informed consent, were included in the study. PrEP choice and study arms Participants were offered a person-centered model providing a choice between same-day delivery of CAB-LA (GSK, Durham, UK) or oral PrEP with TDF/FTC (Banvler, Taboão da Serra, Brazil). To support decision-making, participants were allocated in one of the two study arms: (1) education and counseling about HIV combined prevention from a health care provider according to local standard of care (SOC), or (2) exposure to an mHealth intervention tool plus SOC (mHealth + SOC). The first half of the participants enrolled in each site received SOC and the remaining participants received mHealth + SOC. The person-centered model was based on shared decision-making principles, in which healthcare providers facilitated a non-directive discussion aimed at eliciting participants' personal values, priorities, and lifestyle needs, such as daily routines or privacy preferences. The mHealth tool acted as a decision aid, providing information on each PrEP modality to ensure that the final choice was informed, autonomous, and aligned with the participant's individual needs. mHealth intervention The mHealth tool was developed through a co-creation process to ensure the intervention was grounded in person-centered principles. Guided by the Information-Motivation-Behavioral Skills (IMB) model, the content focused on HIV prevention education to empower participants to make autonomous informed choices. A multidisciplinary team of specialists in infectious diseases, public health and education draft the initial prototype. Subsequently, LGBTQIAPN + community leaders from nongovernmental organizations (NGOs) reviewed the content to ensure it was person-centered, culturally sensitive, and addressed specific community barriers to PrEP choice.16 The prototype was then refined based on the feedback from 12 focus group discussions involving 92 sexual and gender diverse individuals aged 18–30 years.17 A qualitative study with 72 ImPrEP participants confirmed that the mHealth tool was useful and appropriate for PrEP education and decision-making support.4 The mHealth intervention tool was delivered to participants via a tablet. It consisted of five video modules (totaling 17 min) with the following subjects: 1) Do you know oral PrEP?; 2) A new modality to prevent HIV: injectable PrEP; 3) Choosing oral PrEP; 4) Choosing injectable PrEP; 5) Choosing other prevention modalities, such as PEP, condoms and treatment as prevention. The video modules featured a diverse, multiracial cast of young sexual and gender diverse persons. All videos had audio and subtitles in Portuguese, as well as sign language (Libras) for accessibility. Participants could watch the videos in privacy. A detailed description of the video content can be found elsewhere.4 Following the mHealth intervention, participants received SOC and could clarify any questions regarding the video content with a health care provider before choosing their preferred PrEP modality. Outcomes The primary outcome was the choice between CAB-LA or oral PrEP, representing the implementation outcome of adoption (uptake) based on the Proctor et al. (2011) framework.18 The secondary implementation outcome was the acceptability of the mHealth intervention tool, in which questions were adapted from established implementation science frameworks, focusing on key constructs: Usability, comprehensibility, and satisfaction.18 Questions included: How did you like the tool, how difficult was it use, how acceptable, comprehensible, and useful was it for you. All responses were provided using a 5-point Likert scale: “Not at all”, “Not that bad”, “Neutral”, “Somewhat satisfied” and “Strongly satisfied”. The Cronbach's alpha for the acceptability items was 0.75, indicating acceptable internal consistency. Decisional Conflict Scale The 16-item Decisional Conflict Scale (DCS) was developed to gather information on participant decisions and the factors influencing choices perceived as effective.19 DCS remains the most widely used and validated tool globally to measure decisional conflict across diverse medical contexts,20 including in the HPTN 084, a phase 3 clinical trial that evaluated CAB-LA efficacy.21 DCS has been translated to and validated in Portuguese, including in the Brazilian context.22,23 It measures three dimensions: knowledge and value attributed to options in the decision-making (7 items; e.g., “I am clear about the best choice for me”); effective decision (6 items; e.g., “I'm happy with my decision”), and support for making the decision (3 items; e.g., “I'm choosing without pressure from others”).23 Responses were assessed on a 5-point Likert scale ranging from 0 (strongly agree) to 4 (strongly disagree). We calculated the total score and scores per dimension as follows: 1) summing items' responses, 2) dividing by number of items, and 3) multiplying by 25. Scores ranged from 0 (no decisional conflict) to 100 (extremely high decisional conflict). The internal consistency (Cronbach's alpha) for the DCS in our sample was 0.82, indicating good internal consistency. Reasons for choosing PrEP modality Participants were asked if they were confident to continue using the PrEP modality chosen (responses in 5-Likert scale from ‘not at all’ to ‘completely sure’). Participants were asked about the reasons for choosing CAB-LA and oral PrEP from a pre-defined response list. Sociobehavioral questionnaire Participants completed a sociobehavioral questionnaire. For this analysis, gender was described as one of the following categories: cisgender man, transgender woman or travesti, transgender man, non-binary person and queer. Age at enrollment was presented using the median and interquartile range (IQR). Age was categorized into three groups (18–20, 21–24, and 25–30 years) to allow comparisons between emerging adults (18–20 years) and young adults (21–24 and 25–30), whose behavior and epidemiological profiles may differ. Sexual and gender diverse populations aged 18–24 years are key priority groups for HIV prevention in Brazil, and subdividing this age range enables a more granular assessment of PrEP modality preferences among the youngest participants (18–20 years), who often face unique barriers to adherence and healthcare access.6 Participants' self-identified race was grouped according to the Brazilian census classification into Asian, Black, Indigenous, Pardo (mixed-race), and White. Educational was categorized into three strata as follows: Less than secondary, secondary (completed), and tertiary or more. Sexual behavior was evaluated through questions related to the number of sex partners, which was described using the median and IQR, and categorized into 0 to 4, 5 to 10, and 11 or more partners following previous analysis24; condomless receptive anal sex (yes/no), and engagement in transactional sex (defined as exchanging sex for money, drugs, gifts, or favors; yes/no). Binge drinking was defined as consumption of five or more drinks within a 2-h timeframe (yes/no). Substance use encompassed the use of club drugs (e.g., ecstasy, LSD, and GHB), cocaine (powder, crack, or paste—an intermediary substance produced during cocaine production), poppers, or other inhalants. Chemsex was defined as use before or during sex of any substance previously reported. Any sexually transmitted infection (STI) was defined as reporting diagnosis of or treatment for syphilis, gonorrhea or chlamydia. Questions regarding sexual behavior, substance use and STIs referred to the six months before enrollment. Statistical analysis Participant characteristics were described overall and by PrEP choice (CAB-LA or oral PrEP) to evaluate associations with the outcome, and by study arm (SOC vs. mHealth + SOC) to assess potential baseline imbalances between groups. Differences between groups were assessed using the chi-squared test for categorical variables and the Wilcoxon rank-sum test for continuous variables with asymmetric distributions. Reasons reported by participants for choosing CAB-LA or oral PrEP, as well as the acceptability of the mHealth tool among participants exposed to the intervention, were summarized descriptively using frequencies and percentages. Modified Poisson regression models with robust error variance25 were used to estimate prevalence ratios (PRs) and corresponding 95% confidence intervals (CIs) for the effects of our exposures of interest, study arm (SOC vs. mHealth + SOC) and Decisional Conflict Scale (DCS), on CAB-LA choice. We constructed Directed Acyclic Graphs (DAGs) based on a priori knowledge to map the assumed causal inter-relationships between each exposure of interest, CAB-LA choice, and other covariates. These DAGs guided the selection of variables to be included in multivariable regression models, ensuring that confounding was specifically addressed for each exposure-outcome association (Appendix A, Multimedia Component 1). Based on them, study site was the only potential confounder of the association between study arm and PrEP choice. Therefore, we first evaluated the effect of study arm on choosing CAB-LA adjusted for site (Model 1). To ensure the robustness of the Model 1 findings, we performed a sensitivity analysis by adding sociodemographic and behavioral characteristics into the multivariable regression model (Model 2). This allowed us to verify the consistency of the primary associations while accounting for potential imbalances between participants enrolled in different recruitment phases. To evaluate association between DCS and CAB-LA choice, study arm, site, and sociodemographic and behavioral characteristics were identified as potential confounders and therefore included in the multivariable regression model (Model 3). No evidence of non-linearity was observed for DCS in quadratic term (p = 0.13). Multicollinearity was assessed using Variance Inflation Factors (VIFs) to ensure the reliability and stability of the estimated regression coefficients for all exposures of interest. No evidence of relevant multicollinearity was observed. Analyses were performed using SAS version 9.4. Role of the funding source The funding bodies had no role in the study design, data collection, data analysis, data interpretation, writing and decision to submit the paper for publication. ViiV Healthcare provided CAB-LA for the study. Results Overall, 2921 pre-eligible individuals were assessed from October 2023 to October 2024, with 503 (17.2%) declining to participate and 994 (34.0%) deemed ineligible. Among the latter (n = 994), the main reasons for ineligibility were prior PrEP use (53.7%), HIV positive test (22.9%), and PEP indication (13.3%) (Fig. 1). A total of 1447 eligible participants were enrolled, of whom 1201 (83.0%) chose CAB-LA, and 246 (17.0%) chose oral PrEP.Fig. 1Study flow-chart. Study flow-chart. A total of 738 (51.0%) participants were allocated to the SOC arm, and 709 (49.0%) to the mHealth + SOC arm (Table 1). Overall, most participants self-identified as cisgender man (1318; 91.1%), 76 (5.2%) as transgender women or travesti, 33 (2.3%) as non-binary persons, 14 (1.0%) as transgender men, and 3 (0.2%) as queer. The median age was 26 years (IQR: 23–28), and 556 (38.4%) participants were aged 18–24 years. Most participants were Black or Pardo (842; 58.2%), had secondary education or lower (894; 61.8%), and reported 5 or more sex partners (750; 51.8%), condomless receptive anal sex (965; 66.7%), transactional sex (85; 5.9%) and binge drinking (1098; 75.9%). Substance use, chemsex and any STI were reported by 399 (27.6%), 173 (12.0%), and 189 (13.1%) participants, respectively. Most participants showed very low decisional conflict (DCS total mean score 1.9, standard deviation [SD] 4.8), with 1179 (81.5%) believing that they will continue using the PrEP modality chosen.Table 1Participant characteristics at enrollment overall and according to PrEP choice.TotalTotal N (%)CAB-LA n (%)Oral n (%)P-valueaN = 1447 (100%)n = 1201 (83.0%)N = 246 (17.0%)Study arm<0.0001 SOC738 (51.0)566 (47.1)172 (70.9) mHealth + SOC709 (49.0)635 (52.9)74 (30.1)Site<0.0001 Campinas243 (16.8)199 (16.6)44 (17.9) Florianópolis198 (13.7)130 (10.8)68 (27.6) Manaus224 (15.5)176 (14.6)48 (19.5) Rio de Janeiro292 (20.2)256 (21.3)36 (14.6) Salvador242 (16.7)223 (18.6)19 (7.7) São Paulo248 (17.1)217 (18.1)31 (12.6)Gender0.80 Cisgender man1318 (91.1)1090 (90.8)228 (92.7) Transgender woman/Travesti76 (5.2)66 (5.5)10 (4.1) Transgender man14 (1.0)13 (1.1)1 (0.4) Non-binary33 (2.3)27 (2.2)6 (2.4) Queer3 (0.2)3 (0.2)0 (0.0) Preferred not to answer3 (0.2)2 (0.2)1 (0.4)Age, years Median (IQR)26 (23–28)26 (23–28)25 (22–28)0.22 18–20131 (9.0)100 (8.3)31 (12.6)0.33 21–24425 (29.4)353 (29.4)72 (29.3) 25–30891 (61.6)748 (62.3)143 (58.1)Race/Ethnicity0.20 Asian13 (0.9)11 (0.9)2 (0.8) Black343 (23.7)299 (24.9)44 (17.9) Indigenous13 (0.9)10 (0.8)3 (1.2) Pardo499 (34.5)406 (33.8)93 (37.8) White579 (40.0)475 (39.6)104 (42.3)Education Less than secondary60 (4.2)46 (3.8)14 (5.7)0.33 Secondary834 (57.6)699 (58.2)135 (54.9) Tertiary553 (38.2)456 (8.0)97 (39.4)Number of sex partnersb Median (IQR)5 (3–10)5 (2–10)4 (3–10)0.60 0–4697 (48.2)567 (47.2)130 (52.8)0.27 5–10460 (31.8)389 (32.4)71 (28.9) 11 or more290 (20.0)245 (20.4)45 (18.3)Condomless receptive anal sexb0.052 Yes965 (66.7)814 (67.8)151 (61.4) No482 (33.3)387 (32.2)95 (38.6)Engagement in transactional sexb0.87 Yes85 (5.9)70 (5.8)15 (6.1) No1361 (94.0)1130 (94.1)231 (93.9) Preferred not to answer1 (0.1)1 (0.1)0 (0.0)Binge drinkingb0.46 Yes1098 (75.9)917 (76.3)181 (73.6) No346 (23.9)283 (23.6)63 (25.6) Preferred not to answer3 (0.2)1 (0.1)2 (0.8)Substance useb0.65 Yes399 (27.6)334 (27.8)65 (26.4) No1041 (71.9)861 (71.7)180 (73.2) Preferred not to answer7 (0.5)6 (0.5)1 (0.4)Chemsexb,c0.74 Yes173 (12.0)142 (11.8)31 (12.6) No1267 (87.5)1053 (87.7)214 (87.0) Preferred not to answer7 (0.5)6 (0.5)1 (0.4)Any STIb0.29 Yes189 (13.1)162 (13.5)27 (11.0) No1258 (86.9)1039 (86.5)219 (89.0)Confident that will continue using the PrEP modality chosen0.36 Not at all0 (0.0)0 (0.0)0 (0.0) Low chance3 (0.2)2 (0.2)1 (0.4) I don't know8 (0.5)5 (0.4)3 (1.2) Almost sure257 (17.8)211 (17.6)46 (18.7) Completely sure1179 (81.5)983 (81.8)196 (79.7)Decisional Conflict Scale (mean, SD) Total1.9 (4.8)1.6 (3.3)3.4 (8.7)<0.0001 Knowledge and value attributed to options in the decision-making1.0 (4.6)0.8 (3.0)2.0 (8.9)0.010 Effective decision-making2.7 (6.8)2.3 (5.6)5.1 (10.7)<0.0001 Support for decision-making2.2 (7.2)2.0 (6.5)3.2 (10.0)0.097Substance use was defined as use of any: Club drugs (eg, ecstasy, lysergic acid diethylamide, and gamma-hydroxybutyrate), cocaine (powder, crack, or paste), poppers, and other inhalants.aPearson's Chi-squared test; Fisher's exact test; Wilcoxon rank sum test. PrEP: pre-exposure prophylaxis.bPast 6 months.cDefined as any illicit substance use (except marijuana) before or during sex. Table 1Participant characteristics at enrollment overall and according to PrEP choice.TotalTotal N (%)CAB-LA n (%)Oral n (%)P-valueaN = 1447 (100%)n = 1201 (83.0%)N = 246 (17.0%)Study arm<0.0001 SOC738 (51.0)566 (47.1)172 (70.9) mHealth + SOC709 (49.0)635 (52.9)74 (30.1)Site<0.0001 Campinas243 (16.8)199 (16.6)44 (17.9) Florianópolis198 (13.7)130 (10.8)68 (27.6) Manaus224 (15.5)176 (14.6)48 (19.5) Rio de Janeiro292 (20.2)256 (21.3)36 (14.6) Salvador242 (16.7)223 (18.6)19 (7.7) São Paulo248 (17.1)217 (18.1)31 (12.6)Gender0.80 Cisgender man1318 (91.1)1090 (90.8)228 (92.7) Transgender woman/Travesti76 (5.2)66 (5.5)10 (4.1) Transgender man14 (1.0)13 (1.1)1 (0.4) Non-binary33 (2.3)27 (2.2)6 (2.4) Queer3 (0.2)3 (0.2)0 (0.0) Preferred not to answer3 (0.2)2 (0.2)1 (0.4)Age, years Median (IQR)26 (23–28)26 (23–28)25 (22–28)0.22 18–20131 (9.0)100 (8.3)31 (12.6)0.33 21–24425 (29.4)353 (29.4)72 (29.3) 25–30891 (61.6)748 (62.3)143 (58.1)Race/Ethnicity0.20 Asian13 (0.9)11 (0.9)2 (0.8) Black343 (23.7)299 (24.9)44 (17.9) Indigenous13 (0.9)10 (0.8)3 (1.2) Pardo499 (34.5)406 (33.8)93 (37.8) White579 (40.0)475 (39.6)104 (42.3)Education Less than secondary60 (4.2)46 (3.8)14 (5.7)0.33 Secondary834 (57.6)699 (58.2)135 (54.9) Tertiary553 (38.2)456 (8.0)97 (39.4)Number of sex partnersb Median (IQR)5 (3–10)5 (2–10)4 (3–10)0.60 0–4697 (48.2)567 (47.2)130 (52.8)0.27 5–10460 (31.8)389 (32.4)71 (28.9) 11 or more290 (20.0)245 (20.4)45 (18.3)Condomless receptive anal sexb0.052 Yes965 (66.7)814 (67.8)151 (61.4) No482 (33.3)387 (32.2)95 (38.6)Engagement in transactional sexb0.87 Yes85 (5.9)70 (5.8)15 (6.1) No1361 (94.0)1130 (94.1)231 (93.9) Preferred not to answer1 (0.1)1 (0.1)0 (0.0)Binge drinkingb0.46 Yes1098 (75.9)917 (76.3)181 (73.6) No346 (23.9)283 (23.6)63 (25.6) Preferred not to answer3 (0.2)1 (0.1)2 (0.8)Substance useb0.65 Yes399 (27.6)334 (27.8)65 (26.4) No1041 (71.9)861 (71.7)180 (73.2) Preferred not to answer7 (0.5)6 (0.5)1 (0.4)Chemsexb,c0.74 Yes173 (12.0)142 (11.8)31 (12.6) No1267 (87.5)1053 (87.7)214 (87.0) Preferred not to answer7 (0.5)6 (0.5)1 (0.4)Any STIb0.29 Yes189 (13.1)162 (13.5)27 (11.0) No1258 (86.9)1039 (86.5)219 (89.0)Confident that will continue using the PrEP modality chosen0.36 Not at all0 (0.0)0 (0.0)0 (0.0) Low chance3 (0.2)2 (0.2)1 (0.4) I don't know8 (0.5)5 (0.4)3 (1.2) Almost sure257 (17.8)211 (17.6)46 (18.7) Completely sure1179 (81.5)983 (81.8)196 (79.7)Decisional Conflict Scale (mean, SD) Total1.9 (4.8)1.6 (3.3)3.4 (8.7)<0.0001 Knowledge and value attributed to options in the decision-making1.0 (4.6)0.8 (3.0)2.0 (8.9)0.010 Effective decision-making2.7 (6.8)2.3 (5.6)5.1 (10.7)<0.0001 Support for decision-making2.2 (7.2)2.0 (6.5)3.2 (10.0)0.097Substance use was defined as use of any: Club drugs (eg, ecstasy, lysergic acid diethylamide, and gamma-hydroxybutyrate), cocaine (powder, crack, or paste), poppers, and other inhalants.aPearson's Chi-squared test; Fisher's exact test; Wilcoxon rank sum test. PrEP: pre-exposure prophylaxis.bPast 6 months.cDefined as any illicit substance use (except marijuana) before or during sex. Participant characteristics at enrollment overall and according to PrEP choice. Substance use was defined as use of any: Club drugs (eg, ecstasy, lysergic acid diethylamide, and gamma-hydroxybutyrate), cocaine (powder, crack, or paste), poppers, and other inhalants. Pearson's Chi-squared test; Fisher's exact test; Wilcoxon rank sum test. PrEP: pre-exposure prophylaxis. Past 6 months. Defined as any illicit substance use (except marijuana) before or during sex. Most sociodemographic and behavioral characteristics were similar between participants who chose CAB-LA and oral PrEP (Table 1). However, the distribution of PrEP modality differed significantly across study sites and study arms. The proportion of participants receiving mHealth + SOC was higher among those who chose CAB-LA than among those who chose oral PrEP (52.9% vs. 30.1%, respectively). Participants who chose CAB-LA had lower mean decisional conflict scores than those who chose oral PrEP (1.6 [SD 3.3] vs. 3.4 [SD 8.7]; p < 0.001). Similar differences were observed for the DCS domains related to knowledge and value attributed to options in decision-making (0.8 [SD 3.0] vs. 2.0 [SD 8.9]; p = 0.010) and effective decision-making (2.3 [SD 5.6] vs. 5.1 [SD 10.7]; p < 0.001). The main reasons for choosing CAB-LA were difficulty in remembering to take a daily pill (n = 941/1201; 78.4%), the belief that the injection is more effective than pills (n = 334/1201; 27.8%), and concerns about the side effects of daily pills (n = 244/1201; 20.3%) (Table 2). The main reasons for choosing oral PrEP were dislike of injections (n = 114/246; 46.3%), belief that it is easier to remember to take a daily pill (n = 83/246; 33.7%), and difficulty attending the clinic bimonthly for injections (n = 60/246; 24.4%).Table 2Reasons for choosing CAB-LA or oral PrEP.Reasons for choosing CAB-LA (N = 1201)n (%)Difficulty remembering to take a daily pill941 (78.4)Belief that the injection is more effective than pills334 (27.8)Concerns about the side effects of daily pills244 (20.3)Afraid people will inquire about reasons for taking PrEP if seen taking pills141 (11.7)No place to store pills48 (4.0)Other186 (15.5)Reasons for choosing oral PrEP (N = 246)n (%)Dislike of injections114 (46.3)Easier to remember to take a daily pill83 (33.7)Difficulty attending the clinic bimonthly for injections60 (24.4)Belief that pills are more effective14 (5.7)Concerned about injection side effects29 (11.8)Afraid people will think they live with HIV if seen in clinic bimonthly7 (2.8)Cannot receive injections because of implants or silicone in the gluteal muscles0 (0.0)Other69 (28.0) Table 2Reasons for choosing CAB-LA or oral PrEP.Reasons for choosing CAB-LA (N = 1201)n (%)Difficulty remembering to take a daily pill941 (78.4)Belief that the injection is more effective than pills334 (27.8)Concerns about the side effects of daily pills244 (20.3)Afraid people will inquire about reasons for taking PrEP if seen taking pills141 (11.7)No place to store pills48 (4.0)Other186 (15.5)Reasons for choosing oral PrEP (N = 246)n (%)Dislike of injections114 (46.3)Easier to remember to take a daily pill83 (33.7)Difficulty attending the clinic bimonthly for injections60 (24.4)Belief that pills are more effective14 (5.7)Concerned about injection side effects29 (11.8)Afraid people will think they live with HIV if seen in clinic bimonthly7 (2.8)Cannot receive injections because of implants or silicone in the gluteal muscles0 (0.0)Other69 (28.0) Reasons for choosing CAB-LA or oral PrEP. Most sociodemographic and behavioral characteristics were similar between participants allocated to SOC and mHealth + SOC arms, except for site, binge drinking and chemsex (Appendix A, Multimedia Component 2). Moreover, participants receiving mHealth + SOC showed lower DCS overall scores than those receiving only SOC (1.5 [SD: 4.8] vs. 2.3 [SD: 4.7]; p < 0.001). The same pattern was observed for the three DCS domains. In the Poisson regression model with robust variance, participants allocated to the mHealth + SOC arm were more likely to choose CAB-LA compared to SOC (PR 1.15; 95% CI 1.10–1.21; p < 0.0001) (Model 1; Table 3). This association remained virtually unchanged after additional adjustment for potential imbalances in sociodemographic and behavioral characteristics (PR 1.15; 95% CI 1.10–1.20; p < 0.0001) (Model 2; Table 3), suggesting that these factors did not materially confound the association.Table 3Prevalence ratios for choosing CAB-LA according to study arm and decisional conflict.VariablePR (95% CI)p-valueModel 1a SOC1.00– mHealth + SOC1.15 (1.10–1.21)<0.0001Model 2b SOC1.00– mHealth + SOC1.15 (1.10–1.20)<0.0001Model 3c Decisional Conflict Scale (DCS)0.99 (0.98–0.99)0.0006aAdjusted for site.badjusted for site, sociodemographic, and behavior variables.cadjusted for site, study arm, sociodemographic and behavior variables. Table 3Prevalence ratios for choosing CAB-LA according to study arm and decisional conflict.VariablePR (95% CI)p-valueModel 1a SOC1.00– mHealth + SOC1.15 (1.10–1.21)<0.0001Model 2b SOC1.00– mHealth + SOC1.15 (1.10–1.20)<0.0001Model 3c Decisional Conflict Scale (DCS)0.99 (0.98–0.99)0.0006aAdjusted for site.badjusted for site, sociodemographic, and behavior variables.cadjusted for site, study arm, sociodemographic and behavior variables. Prevalence ratios for choosing CAB-LA according to study arm and decisional conflict. Adjusted for site. adjusted for site, sociodemographic, and behavior variables. adjusted for site, study arm, sociodemographic and behavior variables. In the model evaluating the DCS, higher scores were associated with a lower prevalence ratio of choosing CAB-LA. After adjustment for the study arm, site, and sociodemographic and behavioral characteristics, each one-point increase in the DCS was associated with a reduction in the prevalence ratio of choosing CAB-LA (PR 0.99; 95% CI 0.98–0.99; p = 0.0006) (Model 3; Table 3). Table 4 describes the acceptability of the mHealth tool to support choice. Most participants were strongly satisfied with learning using the tablet (605; 85.3%) and found the mHealth tool very easy to use (663; 93.5%). The time to complete all videos was deemed very acceptable by 482 (67.9%) participants. Almost all participants found the information comprehensible (676; 95.3%), useful or extremely useful in supporting their PrEP decision (659; 92.9%) and were somewhat or extremely satisfied with the mHealth tool (679; 95.7%).Table 4Acceptability of the mHeath tool designed for the ImPrEP CAB Brasil study.TotalTotal N (%)CAB-LA n (%)Oral n (%)709 (100.0)635 (89.6)74 (10.4)How much did you like learning with the tablet? Not at all3 (0.4)3 (0.5)0 (0.0) Not that bad17 (2.4)15 (2.4)2 (2.7) Neutral22 (3.1)20 (3.1)2 (2.7) Somewhat satisfied62 (8.8)53 (8.3)9 (12.2) Strongly satisfied605 (85.3)544 (85.7)61 (82.4)How difficult was to use the mHealth tool? Very difficult4 (0.6)3 (0.5)1 (1.4) Somewhat difficult2 (0.3)1 (0.2)1 (1.4) Neither difficult nor easy10 (1.4)7 (1.1)3 (4.0) Somewhat easy30 (4.2)27 (4.2)3 (4.0) Very easy663 (93.5)597 (94.0)66 (89.2)How acceptable was the time to complete all videos? Not acceptable at all7 (1.0)6 (0.9)1 (1.4) Not very acceptable15 (2.1)12 (1.9)3 (4.0) Neutral16 (2.3)15 (2.4)1 (1.4) Somewhat acceptable189 (26.7)170 (26.8)19 (25.7) Very acceptable482 (67.9)432 (68.0)50 (67.5)How comprehensible was the information? I did not understand anything0 (0.0)0 (0.0)0 (0.0) I did not understand most0 (0.0)0 (0.0)0 (0.0) I understood about half4 (0.6)3 (0.5)1 (1.4) I understood most29 (4.1)22 (3.5)7 (9.5) I understood everything676 (95.3)610 (96.0)66 (89.1)How useful was the mHealth in supporting the PrEP decision? Not at all5 (0.7)4 (0.6)1 (1.4) Not very useful16 (2.3)14 (2.2)2 (2.7) Somewhat useful29 (4.1)23 (3.6)6 (8.1) Useful197 (27.8)176 (27.7)21 (28.4) Extremely useful462 (65.1)418 (65.9)44 (59.4)How would you rate your overall satisfaction with the mHealth tool? Extremely dissatisfied5 (0.7)5 (0.8)0 (0.0) Somewhat dissatisfied4 (0.6)4 (0.6)0 (0.0) Neutral21 (3.0)17 (2.7)4 (5.4) Somewhat satisfied66 (9.3)57 (9.0)9 (12.2) Extremely satisfied613 (86.4)552 (86.9)61 (82.4) Table 4Acceptability of the mHeath tool designed for the ImPrEP CAB Brasil study.TotalTotal N (%)CAB-LA n (%)Oral n (%)709 (100.0)635 (89.6)74 (10.4)How much did you like learning with the tablet? Not at all3 (0.4)3 (0.5)0 (0.0) Not that bad17 (2.4)15 (2.4)2 (2.7) Neutral22 (3.1)20 (3.1)2 (2.7) Somewhat satisfied62 (8.8)53 (8.3)9 (12.2) Strongly satisfied605 (85.3)544 (85.7)61 (82.4)How difficult was to use the mHealth tool? Very difficult4 (0.6)3 (0.5)1 (1.4) Somewhat difficult2 (0.3)1 (0.2)1 (1.4) Neither difficult nor easy10 (1.4)7 (1.1)3 (4.0) Somewhat easy30 (4.2)27 (4.2)3 (4.0) Very easy663 (93.5)597 (94.0)66 (89.2)How acceptable was the time to complete all videos? Not acceptable at all7 (1.0)6 (0.9)1 (1.4) Not very acceptable15 (2.1)12 (1.9)3 (4.0) Neutral16 (2.3)15 (2.4)1 (1.4) Somewhat acceptable189 (26.7)170 (26.8)19 (25.7) Very acceptable482 (67.9)432 (68.0)50 (67.5)How comprehensible was the information? I did not understand anything0 (0.0)0 (0.0)0 (0.0) I did not understand most0 (0.0)0 (0.0)0 (0.0) I understood about half4 (0.6)3 (0.5)1 (1.4) I understood most29 (4.1)22 (3.5)7 (9.5) I understood everything676 (95.3)610 (96.0)66 (89.1)How useful was the mHealth in supporting the PrEP decision? Not at all5 (0.7)4 (0.6)1 (1.4) Not very useful16 (2.3)14 (2.2)2 (2.7) Somewhat useful29 (4.1)23 (3.6)6 (8.1) Useful197 (27.8)176 (27.7)21 (28.4) Extremely useful462 (65.1)418 (65.9)44 (59.4)How would you rate your overall satisfaction with the mHealth tool? Extremely dissatisfied5 (0.7)5 (0.8)0 (0.0) Somewhat dissatisfied4 (0.6)4 (0.6)0 (0.0) Neutral21 (3.0)17 (2.7)4 (5.4) Somewhat satisfied66 (9.3)57 (9.0)9 (12.2) Extremely satisfied613 (86.4)552 (86.9)61 (82.4) Acceptability of the mHeath tool designed for the ImPrEP CAB Brasil study. Discussion This novel person-centered PrEP choice implementation study demonstrated a strong preference for CAB-LA among young sexual and gender diverse persons in Brazil and highlighted the significant role of an mHealth tool in supporting PrEP decision-making. Most participants chose CAB-LA, with the main reason being the perceived difficulty of daily oral pill intake. Our results are consistent with previous surveys and a discrete choice experiment conducted with sexual and gender diverse persons in Latin America, showing a preference for long-acting injectable PrEP.14,26,27 The mHealth tool for decision-making support was highly acceptable. Participants exposed to the mHealth tool showed lower decisional conflict scores when choosing CAB-LA. Model results indicated that the mHealth tool increased the prevalence ratio of choosing CAB-LA, whereas higher decisional conflict scores decreased the prevalence ratio of choosing CAB-LA. In the current era of multiple effective HIV prevention options, providing knowledge and encouraging informed decision-making will likely lead to improved outcomes. Recent studies highlight a strong preference for CAB-LA over oral PrEP across various populations and settings. A high preference for CAB-LA was reported in the HIV Prevention Trials Network (HPTN) studies 083 and 084 open-label extensions. In HPTN083, among 2592 MSM and transgender women from Latin America (n = 1193), the U.S. (n = 803), Asia (n = 515), and Africa (n = 81), 96% chose CAB-LA with no difference among regions.28 In HPTN084, among 2472 cisgender women from Africa, 78% chose CAB-LA.21 To date, only one implementation study has reported data on PrEP choice with CAB-LA. In rural Uganda and Kenya, 374 (56%) of 485 persons aged 15 years and older who participated in the SEARCH dynamic choice HIV prevention program opted for CAB-LA.9 In a study conducted in Cape Town, South Africa, preference for CAB-LA over oral PrEP was high among pregnant and breastfeeding participants (77%; n = 23/30 and 89%; n = 25/28, respectively).29 Among 62 cisgender women who inject drugs in Philadelphia (U.S.), 89% chose CAB-LA over oral PrEP.30 However, challenges in implementing CAB-LA persist. In the U.S., despite initially promising results, CAB-LA accounts for only 1.4% of all PrEP use. A low-barrier, same-day/next-day initiation program for CAB-LA in San Francisco, primarily focused on cisgender MSM in a safety net setting, highlighted a potential path for wider implementation.31 In California, among 19,676 individuals dispensed PrEP, only 141 (0.7%) were administered CAB-LA between December 2021 and June 2024.32 In a primary care center in the U.S. South, of 221 persons referred to CAB-LA, only 77 (35%) initiated it due to barriers related to delays in program scheduling and medication procurement.33 Taken together, these findings underscore a strong demand for CAB-LA, yet reveal critical implementation barriers that must be addressed to realize its full preventive potential globally. The high preference for CAB-LA observed in our study cohort directly addresses barriers related to oral PrEP uptake and persistence. Globally, rates of oral PrEP uptake and persistence remain suboptimal, with estimates suggesting that 41% of users discontinue its use within six months.34 PrEP choice is poised to be a game changer for HIV prevention as end-users are offered the option to choose among HIV prevention products, including oral PrEP, CAB- LA, lenacapavir, and additional products currently in the development pipeline. Our results align with previously reported preferences for long-acting injectable PrEP among sexual and gender diverse populations in Latin America,14,26,27 indicating its potential as a more acceptable and sustainable prevention modality in real-world settings. This reinforces the notion that offering diverse PrEP options tailored to individual preferences can significantly enhance uptake, engagement, and persistence. Overall, participants showed low decisional conflict, as measured by the DCS. However, those exposed to the mHealth tool (vs. SOC only) and those choosing CAB-LA (vs. oral PrEP) showed lower decisional conflict scores. In the HPTN084 open-label extension, participants choosing oral PrEP had higher scores in the DCS effective decision domain (CAB: median 6 [IQR: 0–25] and oral PrEP: median 13 [IQR: 0–25]; p = 0.015).21 These results suggest that individuals opting for CAB-LA generally felt more confident and clear in their decision-making, possibly due to perceived advantages or alignment with personal preferences. Conversely, those selecting oral PrEP may experience greater uncertainty, underscoring the importance of tailored counseling and decision support to ensure that all individuals can make informed, confident choices aligned with their needs and circumstances. In our study, the proportion of participants of younger age (18–20 years) choosing CAB-LA was lower than that of those aged 25–30 years (12.6% vs. 8.3%, respectively). This is aligned with results from a previous PrEP choice study conducted among 261 sexual and gender diverse persons aged 15–19 years; among those aged 18–19 years (n = 186), only 53 (28.5%) chose CAB-LA.35 In a large survey conducted in Latin America, increased odds of preferring daily oral PrEP were confirmed for Brazilian MSM aged 18–24 years compared to MSM aged >24 years.14 This suggests specific considerations for younger individuals, who might benefit from long-acting PrEP modalities due to challenges related to oral PrEP adherence.24 Furthermore, they might require more intensive peer-led counseling or tailored information to overcome potential barriers, such as concerns about needles or navigating complex health decisions. Other long-acting modalities under investigation, such as monthly oral PrEP with MK-8527,36 may be alternative options for this population. The mHealth tool's impact on decision-making and CAB-LA choice represents a pivotal evidence-based contribution, filling a recognized gap regarding digital tools in PrEP decision-making. A recent systematic review identified only 12 clinical trials that evaluated the effectiveness of digital health interventions in enhancing the PrEP continuum among MSM; none were conducted in Latin America.12 The high acceptability of the mHealth tool shown here, with over 90% of participants finding it comprehensible, useful, and easy to use, validates its potential as a scalable and effective strategy for informed decision support within public health systems. Such accessible digital platforms can empower individuals by providing comprehensive information about PrEP modalities, thereby reducing decisional conflict and facilitating autonomous, person-centered choices, particularly in resource-constrained environments. The high acceptability and impact of the mHealth tool may also be attributed to its intentional design, which focuses on representation and cultural competence. By using relatable actors and community-validated language, the tool moved beyond simple information delivery to providing a culturally resonant decision aid. This approach may have helped mitigate the historical mistrust or lack of engagement some marginalized groups feel toward traditional, provider-centric healthcare models, thereby facilitating a more equitable adoption of CAB-LA. The mHealth tool offers a scalable, low-cost strategy to support PrEP choice within public health systems. While more complex digital solutions, such as AI-driven chatbots, are emerging, our standardized video-based mHealth approach ensures consistent information delivery and accessibility (e.g., sign language), making it particularly suitable for large-scale implementation within public health systems like Brazil's SUS. Furthermore, the innovation of our intervention lies in its evidence-based co-creation, grounded in qualitative insights from focus groups, enabling a highly tailored experience that directly addresses the needs of young sexual and gender diverse populations in Brazil. Although the initial development phase incurs costs for culturally competent content production, subsequent operational costs are low because the tool can be deployed on existing clinic hardware or accessed via personal mobile devices. Importantly, the tool simplifies the implementation process by standardizing the delivery of complex information about PrEP modalities, reducing the time and training required for healthcare providers to conduct comprehensive counseling sessions and potentially increasing the efficiency of service delivery in resource-constrained settings. A major strength of this study was its sample size, making it the largest CAB-LA cohort in Latin America. Moreover, the study was conducted at public health PrEP clinics in Brazil, where the population can access oral PrEP. However, this study had several limitations. The study population was specific to persons aged 18–30 years who self-identified as cisgender men, transgender, and non-binary persons, limiting direct generalizability to other populations or age groups. The study had important limitations related to its quasi-experimental design. The use of sequential allocation is susceptible to temporal effects (history bias); for instance, as the study progressed, healthcare providers may have become more proficient in discussing CAB-LA, or community awareness of injectable PrEP may have increased, potentially overestimating the independent effect of the mHealth tool. Furthermore, selection bias cannot be entirely ruled out, as individuals who enrolled earlier in the study (SOC arm) might have differed in their baseline motivation or risk perception from those who enrolled later (mHealth + SOC arm). Although we adjusted for sociodemographic and behavioral factors in our multivariable analysis, unmeasured confounding may have influenced participant choices such as shifts in social media discourse or external news regarding long-acting PrEP during the study period, as well as structural, community-level, or other individual-level variables such as socioeconomic status, access to healthcare and social support. Our results are promising but represent only the initial step regarding an informed choice of a PrEP product. Longitudinal analysis considering participants engagement over time are fundamental to understand if CAB-LA also improves persistence within the PrEP program, as compared to oral PrEP. Our findings highlight the need for equitable expansion of CAB-LA across national public health systems, including in Brazil. Ensuring equity will require the availability of diverse and affordable PrEP modalities. Current PrEP delivery models and persistent inequities continue to leave populations at higher vulnerability behind, but integrating multiple PrEP modalities and mHealth decision-support tools into the Brazilian SUS could close these gaps and serve as a model for Latin America. Lastly, access to long-acting PrEP modalities remains constrained by high prices and regulatory hurdles, underscoring the urgent need for policy action to ensure new PrEP modalities are available and affordable for all. In conclusion, the ImPrEP CAB Brasil study demonstrated a strong preference for CAB-LA PrEP among young sexual and gender diverse populations in Brazil, facilitated by a highly acceptable and effective decision-making support mHealth tool. These findings underscore the critical importance of integrating diversified PrEP modalities with accessible decision-making support interventions within public health systems. Implementing person-centered choice approaches supported by innovative digital health solutions is paramount for accelerating equitable PrEP access, enhancing its uptake, and advancing global HIV prevention efforts, particularly in high-burden regions. Contributors BG, VGV, BH, MCP, TST, MB, SBS, and GOM conceived and designed the ImPrEP CAB Brasil study. TST, CC, VGV, and BG conceived and supervised the current analysis. RIM, ICL, MC, and HP had access to and verified the data and did the statistical analyses. BH was the study medical coordinator. AF, MPGM, JVM, JNL, and RZ helped with data acquisition and with interpretation of the findings. MTST, EMJ, AR, NP, SWC, and PML helped with interpretation of the findings. JM and KS provided community leadership. TST, BH, and BG wrote the first draft of this manuscript. All authors read and approved the final manuscript. TST and BH had full access to all the data in the study and had final responsibility for the decision to submit for publication. Data sharing statement A complete de-identified dataset sufficient to reproduce this analysis will be made available upon request to the corresponding author, following approval of a concept sheet summarizing the analyses to be done. Declaration of interests ARR and NP are employees of ViiV Healthcare and are stockholders in GSK. ViiV Healthcare provided CAB-LA for the study. All other authors declare no competing interests related to this work.